Search
Back

Ribociclib Succinate

CAS 1374639-75-4
Ribociclib Succinate

General Information

Ribociclib succinate is a type of cyclin-dependent kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. It is used to treat hormone-receptor positive (HR+), HER2 negative (HER2-) breast cancer that is advanced or has spread to other parts of the body.


About the API

Technology Synthetic
Therapeutic category Oncology
Systematic Name 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.